Algeta schedules fourth quarter and full year 2012 results presentation, webcast and conference call
February 18, 2013 - Oslo, Norway
Algeta ASA (OSE: ALGETA), a company focused onthe development of novel targeted cancer therapeutics, will announce itsfourthquarter and full year 2012 results on Thursday, 28 February 2013. Apresentationby Algeta's senior management team to investors, analysts and the presswilltake place in Oslo at 10:00 CET.The presentation will also be webcast live and can be accessed throughwww.algeta.com where questions can also be submitted during thepresentation.
The presentation will take place at 10:00 CET at:
Haakon VIIs gate 1
Algeta's senior management will also host an international conferencecall at14:30 CET/08:30 Eastern Time (US) (details below).
To participate in the conference call, please dial the appropriate numberbelowfive minutes prior to the call:
US: +1 877 423 0830
UK: +44 20 7153 9154
Norway: +47 21 06 61 13
Sweden: +46 8-506 443 86
Denmark: +45 32 71 42 62
Switzerland: +41 44 580 65 22
Participant pin code: 434633#
To access the replay, please dial:
US: +1 877 679 2989
UK: +44 20 3364 5196
Norway: +47 23 50 02 03
Sweden: +46 8-505 564 73
Conference reference: 345360#
A replay version of the conference call will also beavailable atwww.algeta.com.
The results report and the presentation will be available atwww.algeta.com inthe Investors section from 07:00 CET.
Algeta is a company focused on developing novel targeted therapies forpatientswith cancer based on its alpha-pharmaceutical platform. The Company isheadquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,based inCambridge, MA performing commercial marketing operations in the US. Algetaislisted on the Oslo Stock Exchange (Ticker: ALGETA). For more informationpleasevisit www.algeta.com.
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
For further information, please contact:
Mike Booth / Renate Birkeli
+47 23 00 67 32
Communications & Corporate Affairs
+44 207 638 9571
Citigate Dewe Rogerson
+47 22 04 82 00
Gambit Hill & Knowlton
+1 781 235 3060
MacDougall Biomedical Communications
US investor enquiries:
+1 646 378 2953
The Trout Group